title: Celecoxib does not affect the release of hyaluronic acid in end stage osteoarthritic joints.
abstract: OBJECTIVE
  Non-steroidal anti-inflammatory drugs play a major role in the management of osteoarthritis (OA). However, it remains unknown whether these drugs affect cartilage and synovial metabolism in osteoarthritic joints. The aim of this study was to evaluate the effects of a selective cyclooxygenase (COX)-2 inhibitor, celecoxib, on synovial fluids and tissues in severely osteoarthritic knees.
  
  
  METHODS
  Patients were randomized into three groups and medicated two weeks prior to total knee arthroplasty with celecoxib, diclofenac sodium, or no medication (control). We checked for the presence of matrix metalloproteinase-3 (MMP-3), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and hyaluronic acid (HA) in the synovial fluids of all three groups.
  
  
  RESULTS
  MMP-3 significantly decreased in the celecoxib-treated patients (p = 0.0031). On the other hand, there were no significant differences among the three groups in their TNF-α and IL-1β levels. HA in the joint fluid was significantly increased in the diclofenac-treated group, while HA was not changed in the celecoxib-treated patients.
  
  
  CONCLUSIONS
  Our study suggests that celecoxib did not affect the level of HA in the joint fluid in the knee in severe OA, in contrast to the effect of the dual COX inhibitor.
authors.affiliation: Department of Joint Replacement and Tissue Engineering, Hokkaido University Graduate School of Medicine, Kita-15, Nishi-7, Kita-ku, Sapporo, 060-8638, Japan.
authors.forename: Daisuke
authors.initials: D
authors.lastname: Takahashi
authors.forename: Tokifumi
authors.initials: T
authors.lastname: Majima
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Onodera
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Kasahara
authors.forename: Masahiro
authors.initials: M
authors.lastname: Inoue
authors.forename: Toru
authors.initials: T
authors.lastname: Irie
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Kasemura
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002358:Cartilage, Articular / Q000187:drug effects / Q000378:metabolism; D000068579:Celecoxib; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D004008:Diclofenac / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000378:metabolism*; D053583:Interleukin-1beta / Q000378:metabolism; D007719:Knee Joint / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D020370:Osteoarthritis, Knee / Q000188:drug therapy* / Q000378:metabolism; D011720:Pyrazoles / Q000494:pharmacology / Q000627:therapeutic use*; D013449:Sulfonamides / Q000494:pharmacology / Q000627:therapeutic use*; D013582:Synovial Fluid / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D053583:Interleukin-1beta; D011720:Pyrazoles; D013449:Sulfonamides; D014409:Tumor Necrosis Factor-alpha; D004008:Diclofenac; D006820:Hyaluronic Acid; D000068579:Celecoxib